Preventing gonorrhea and reinfection
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Prevention is barriers, testing and partner treatment. Those three account for nearly all of it, and the third is the one most often incomplete.
Two newer options exist, doxycycline after exposure and a meningococcal vaccine with partial cross-protection. Both help somewhat, neither is close to reliable for gonorrhea.
Related pages: Gonorrhea
The bottom line
- Condoms reduce but do not eliminate transmission.
- Many infections are symptom-free and found only by screening.
- Simultaneous partner treatment prevents reinfection.
- No licensed gonorrhea vaccine is available.
- How much doxy-PEP will drive antibiotic resistance.
- Whether a dedicated gonorrhea vaccine will reach licensure.
The story, step by step
What the evidence labels mean
What they do and don't cover
What happens
Condoms and dams, rated honestly.
What the research shows
- Used consistently from start to finish, condoms substantially reduce transmission during vaginal and anal sex.
- Water or silicone-based lubricant reduces breakage. Oil-based products damage latex.
- Oral sex transmits gonorrhea in both directions and is the route people most often leave unprotected. Condoms for fellatio and dams for cunnilingus or anilingus reduce it.
- Throat infection is usually symptom-free and is a major reservoir, which is why this gap matters more than it seems.
- Shared sex toys should be covered with a fresh condom for each person, or washed between uses.
- Barriers are not perfect. They reduce the chance per act, which over many acts is a substantial difference, and is not protection.
Why it matters
The oral sex gap is where most people's protection breaks down, and it is the site where resistance is thought to develop.
What's still uncertain
- Condom effectiveness against gonorrhea is estimated rather than precisely measured.
Read more
- CDC: GonorrheaGovernment
- CDC: STI screening recommendationsGovernment
Next: Testing
The second layer
What happens
Screening as prevention, since most infections are silent.
What the research shows
- Annual testing for sexually active women under 25, and for older women with risk factors.
- Testing every three to six months, at all relevant sites, for men who have sex with men, people on HIV PrEP, and people living with HIV.
- Testing with a new partner, or when a partner has other partners, is reasonable at any age.
- Site-specific testing matters: urine alone misses most throat and rectal infections.
- Testing before starting condomless sex with a new partner, with both people tested at all relevant sites, is the practical version of the mutual monogamy advice.
- Remember the window period: a test immediately after an exposure may be too early, and a repeat about two weeks later settles it.
Why it matters
Mutual monogamy only protects if both people were actually tested, at the right sites, after the window period.
What's still uncertain
- Screening intervals are based on modelling and consensus rather than trials.
Read more
- CDC: STI screening recommendationsGovernment
- OwieClear: Is it gonorrhea? Getting tested properlyOwieClear
Next: Partner treatment
Breaking the loop
What happens
The step that prevents immediate reinfection.
What the research shows
- Partners from the previous 60 days need testing and treatment, whether or not they have symptoms.
- Both people abstain for seven days from the later of the two treatments, and until symptoms have gone.
- Expedited partner therapy, where a clinician provides medication for a partner without seeing them, reduces reinfection and is legal in most US states.
- For gonorrhea it has a limitation: the recommended treatment is an injection, so what can be provided is an oral alternative that is less effective. A partner seen in person and treated properly is better.
- Health department partner notification services and anonymous notification tools exist for situations where telling someone directly is difficult or unsafe.
- Retesting at three months catches the reinfections that happen anyway.
Why it matters
Most repeat infections are not treatment failures. They are a partner who was not treated, or sex resumed too early.
What's still uncertain
- EPT effectiveness for gonorrhea specifically is limited by the oral regimen.
Read more
Next: Doxy-PEP
Partial protection
What happens
Doxycycline taken after sex, and where gonorrhea fits in.
What the research shows
- Doxy-PEP means a single dose of doxycycline taken within 72 hours after condomless sex.
- It substantially reduces syphilis and chlamydia. Its effect on gonorrhea is considerably weaker, in the region of a third to a half in trials, because tetracycline resistance in gonorrhea is widespread.
- It is recommended for specific groups, principally men who have sex with men and transgender women with a recent bacterial STI, rather than for everyone.
- Trials in cisgender women have not shown the same benefit, with adherence as one suggested explanation.
- Concerns include selecting for resistance in gonorrhea and in other bacteria, and effects on the normal bacterial populations of the gut and skin. Surveillance is ongoing.
- It is a clinician-prescribed strategy with a discussion attached, not something to improvise.
Why it matters
For gonorrhea specifically, doxy-PEP is the weakest of its three targets. Anyone taking it for syphilis and chlamydia should not treat it as gonorrhea cover.
What's still uncertain
- Long-term resistance effects of doxy-PEP are not yet known.
Read more
- CDC: Doxycycline post-exposure prophylaxisGovernment
- CDC: Antimicrobial-resistant gonorrheaGovernment
Next: A vaccine
Partial, and borrowed
What happens
The vaccine situation, which is unusual.
What the research shows
- No licensed gonorrhea vaccine exists.
- Meningococcal B vaccines, made from outer membrane vesicles, appear to give partial cross-protection against gonorrhea, because the two bacteria are closely related.
- Observational studies suggest a reduction in the region of 30 to 40 percent, which is modest and real.
- Several health authorities have considered or begun offering this vaccine to people at higher risk of gonorrhea on that basis.
- Dedicated gonorrhea vaccines are in clinical trials. None is licensed.
- Partial protection changes the odds and does not replace the rest of this page.
Why it matters
A vaccine borrowed from a different bacterium, giving roughly a third protection, is where this field currently is. It is worth asking about if you are in a higher-risk group.
What's still uncertain
- Cross-protection evidence is observational and estimates vary.
Read more
- CDC: Antimicrobial-resistant gonorrheaGovernment
- CDC: GonorrheaGovernment